D-dimer, Monoclonal Antibody

For Research Use Only. Not for use in diagnostic procedures.

Monoclonal

IgG2b

DD5

Mouse

This item recognises human D-dimer and shows low cross-reactivity with fibrinogen (D-monomer).
D-dimers are the principle degradation products of cross-linked fibrin, released into the bloodstream following the digestion of fibrin clots (thrombus) by the enzyme plasmin, and thus measurement of the level of D-dimer in plasma, can be used as an indication of thrombotic disorders. Conditions in which levels of D-dimer are elevated include deep vein thrombosis (DVT), venous thromboembolism (VTE), cardiovascular disease and disseminated intravascular coagulation (DIC), a possible acute condition arising from surgical operations, septic shock and liver disease.

Purified
Purified IgG - liquid

IgG concentration 1.0mg/ml (lot specific)

Store at 4 degree C or at -20 degree C if preferred. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
Shelf Life: 18 months from date of despatch.

Small volumes of anti-D-DIMER antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS212859 recognises human D-dimer and shows low cross-reactivity with fibrinogen (D-monomer). D-dimers are the principle degradation products of cross-linked fibrin, released into the bloodstream following the digestion of fibrin clots (thrombus) by the enzyme plasmin, and thus measurement of the level of D-dimer in plasma, can be used as an indication of thrombotic disorders. Conditions in which levels of D-dimer are elevated include deep vein thrombosis (DVT), venous thromboembolism (VTE), cardiovascular disease and disseminated intravascular coagulation (DIC), a possible acute condition arising from surgical operations, septic shock and liver disease.

ELISA (EIA), Western Blot (WB)*

Western Blotting: Application Note: This antibody recognises human D-dimer under non-reducing conditions.

69,757 Da

fibrinogen alpha chain

fibrinogen alpha chain; fibrinogen, A alpha polypeptide

Fibrinogen alpha chain

FIBA_HUMAN

The protein encoded by this gene is the alpha component of fibrinogen, a blood-borne glycoprotein comprised of three pairs of nonidentical polypeptide chains. Following vascular injury, fibrinogen is cleaved by thrombin to form fibrin which is the most abundant component of blood clots. In addition, various cleavage products of fibrinogen and fibrin regulate cell adhesion and spreading, display vasoconstrictor and chemotactic activities, and are mitogens for several cell types. Mutations in this gene lead to several disorders, including dysfibrinogenemia, hypofibrinogenemia, afibrinogenemia and renal amyloidosis. Alternative splicing results in two isoforms which vary in the carboxy-terminus. [provided by RefSeq, Jul 2008]

FGA: Fibrinogen has a double function: yielding monomers that polymerize into fibrin and acting as a cofactor in platelet aggregation. Defects in FGA are a cause of congenital afibrinogenemia (CAFBN). This is a rare autosomal recessive disorder characterized by bleeding that varies from mild to severe and by complete absence or extremely low levels of plasma and platelet fibrinogen. The majority of cases of afibrinogenemia are due to truncating mutations. Variations in position Arg-35 (the site of cleavage of fibrinopeptide a by thrombin) leads to alpha- dysfibrinogenemias. Defects in FGA are a cause of amyloidosis type 8 (AMYL8); also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. 2 isoforms of the human protein are produced by alternative splicing.

Protein type: Secreted, signal peptide; Secreted

Chromosomal Location of Human Ortholog: 4q28

Cellular Component: extracellular space; cell surface; fibrinogen complex; extracellular region; plasma membrane; cell cortex; vesicle; external side of plasma membrane

Molecular Function: protein binding, bridging; protein binding; cell adhesion molecule binding; structural molecule activity; receptor binding

Biological Process: protein polymerization; platelet activation; extracellular matrix organization and biogenesis; positive regulation of heterotypic cell-cell adhesion; cell-matrix adhesion; signal transduction; cellular protein complex assembly; platelet degranulation; positive regulation of protein secretion; positive regulation of vasoconstriction; innate immune response; response to calcium ion; blood coagulation; positive regulation of exocytosis

Disease: Amyloidosis, Familial Visceral; Afibrinogenemia, Congenital; Dysfibrinogenemia, Congenital

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.